NorthWest Biotherapeutics Inc (NWBO)

[Doc logic]

sentiment_stocks,

This analysis and the endpoint order does look like the full alpha spend is being passed down from one endpoint to the next. When I first saw the endpoints posted I assumed that this was the case immediately and it seemed so obvious that I didn’t even comment on it as I was assuming market response was factoring this in. When you posted this it still did not occur to me how poorly understood this might be but upon further review and look at the market reaction I understand that folks just don’t get it yet, even some of the analysts out there.

Look at the 1st secondary objective again and you will realize that NWBO believes that SOC patients that were in captured chemo/rad pseudoprogressors that crossed over are doing well and that enough true progressors that crossed over are receiving salvage treatment benefit from L and or combo that it warrants comparison to other historical SOC/placebo. That is a big statement that goes right in line with research I found long ago about salvage therapy repotentiation created by use of DC therapy as well as the relationship of mesenchymal phenotype, created at progression by up to 85% of all tumors, being more susceptible to DC therapy. Putting this endpoint at the number 2 spot suggests a very high degree of confidence that these relationships exist to the point of statistical certainty. Best wishes.